Ali Behbahani, M.D., member of Korro Bio’s board of directors, joined New Enterprise Associates (NEA) in 2007 and is currently a general partner on the healthcare team. He specializes in investments in the biopharmaceutical, medical device, specialty pharmaceutical and healthcare services sectors.
Prior to joining NEA, Ali worked as an intern and later as a consultant in business development at The Medicines Company, a specialty pharmaceutical company developing acute care cardiovascular products. He previously held positions as a venture associate at Morgan Stanley Venture Partners and a healthcare investment banking analyst at Lehman Brothers. He conducted basic science research in the fields of viral fusion inhibition and structural proteomics at the National Institutes of Health and at Duke University.
Ali concurrently earned his M.D. from the University of Pennsylvania School of Medicine and his MBA from the University of Pennsylvania Wharton School, where he graduated with honors and was a Palmer Scholar. He graduated summa cum laude and received his bachelor’s degrees with distinction in biomedical engineering, electrical engineering and chemistry from Duke University.